Mankind Pharma Ltd.NSE: MANKIND

Press Release Mar 18 2026

· Issued by Mankind Pharma Ltd.

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Mankind Pharma Ltd. has announced the acquisition of the Rivotril brand for the Indian market, which includes exclusive rights to manufacture, market, and distribute the product in India. This acquisition reinforces the company's focus on chronic central nervous system therapies and enhances its existing neuro portfolio. The company aims to leverage its distribution network to improve access to Rivotril across healthcare institutions and prescribers in India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Mankind Pharma Ltd. on 6ix

Earlier from Mankind Pharma

Later from Mankind Pharma

All Mankind Pharma news releases